• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by RadNet Inc.

    4/28/25 6:07:44 AM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    RadNet, Inc. Form 10-K/A
    true Filing EX-19.1 2024 FY 0000790526 0000790526 2024-01-01 2024-12-31 0000790526 2024-06-30 0000790526 2025-02-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-K/A

    Amendment No. 1

     

    ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2024

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

     

    For the transition period from ________________to _________________

     

    Commission file number 001-33307

     

    RadNet, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   13-3326724
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)
         
    1510 Cotner Avenue    
    Los Angeles, California   90025
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (310) 478-7808

    Securities registered pursuant to Section 12(b) of the Act:

     

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $.0001 par value   RDNT   NASDAQ Global Market

     

    Securities registered pursuant to Section 12(g) of the Act: None

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

     

    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

                           
    Large accelerated filer ☒ Accelerated filer ☐
    Non-accelerated filer ☐ Smaller reporting company ☐
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

     

    The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $4.2 billion on June 30, 2024 (the last business day of the registrant’s most recently completed second fiscal quarter) based on the closing price for the common stock on the NASDAQ Global Market on June 30, 2024.

     

    The number of shares of the registrant’s common stock outstanding on February 24, 2025, was 74,041,715.

     

     

     

     

       

     

     

    EXPLANATORY NOTE

     

    On March 3, 2025, RadNet, Inc. (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original 10-K”). This Amendment amends the Original 10-K solely to file Exhibit 19.1 (Insider Trading Policy), which was inadvertently omitted from the Original 10-K.

     

    This Amendment speaks as of the original filing date and does not reflect events occurring after the filing of the Original 10-K. No revisions are being made to the Company’s financial statements or any other disclosure contained in the Original 10-K. This Amendment is an exhibit-only filing. Except for the inclusion of Exhibit 19.1, this Amendment does not otherwise update any exhibits as originally filed or previously amended.

     

    In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) and 15d-14(a) of the Exchange Act. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.

      

     

     

     

     

     

     

     

     

     

     2 

     

     

    PART IV

     

    Item 15. Exhibits and Financial Statements Schedule

     

    (a)Documents filed as part of this annual report on Form 10-K

     

    (1) Financial Statements Form 10-K
      Page    Reference

     

    See “Financial Statements” in Item 15 of Form 10-K, which is incorporated by reference.

     

    (2) Financial Statement Schedules

     

    Schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.

     

    (3) Exhibits

     

    The following exhibits are filed herewith or incorporated by reference herein:

     

    Exhibit No.   Description of Exhibit
    3.1   Certificate of Incorporation of RadNet, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 filed with Form 8-K on September 4, 2008).
         
    3.2   Certificate of Amendment to Certificate of Incorporation of RadNet, Inc., a Delaware corporation, dated September 2, 2008 (incorporated by reference to Exhibit 3.2 filed with Form 8-K on September 4, 2008).
         
    3.3   Amended and Restated Bylaws of RadNet, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 filed with Form 8-K on February 6, 2020).
         
    4.1   Description of Securities (incorporated by reference the Description of Common Stock contained in the registration statement on Form S-3ASR filed on December 27, 2022).
         
    10.1*   Equity Incentive Plan, amended and restated as of April 27, 2023 (incorporated by reference to Exhibit 99.1 filed with Form S-8 registration statement on August 9, 2023).
         
    10.2   Form of Incentive Stock Option Agreement for the Equity Incentive Plan (incorporated by reference to Exhibit 99.2 filed with Form S-8 registration statement on August 9, 2023).
         
    10.3*   Form of Nonstatutory Stock Option Agreement for the Equity Incentive Plan (incorporated by reference to Exhibit 99.3 filed with Form S-8 registration statement on August 9, 2023).

     

     

     

     

     

     3 

     

     

         
    10.4*   Form of Stock Award Agreement for the Equity Incentive Plan (incorporated by reference to Exhibit 99.4 filed with Form S-8 registration statement on August 9, 2023).
         
    10.5*   Form of Stock Units Agreement (deferred settlement) for the Equity Incentive Plan (incorporated by reference to Exhibit 99.5 filed with Form S-8 registration statement on August 9, 2023).
         
    10.6*   Nonqualified Deferred Compensation Plan, effective as of May 5, 2016 (incorporated by reference to Exhibit 10.1 filed with Form 8-K on May 9, 2016).
         
    10.7*   Form of Indemnification Agreement between the Company and each of its officers and directors (incorporated by reference to Exhibit 10.1 filed with Form 8-K on June 14, 2021).
         
    10.8*   Employment Agreement dated as of April 20, 2023 with Howard G. Berger, M.D. (incorporated by reference to Exhibit 10.1 filed with Form 8-K on April 26, 2023).
         
    10.9*   Amendment to Employment Agreement dated January 1, 2024 with Howard G. Berger, M.D. (incorporated by reference to Exhibit 10.9 filed with Form 10-K on February 29, 2024).
         
    10.10*   Employment Agreement dated September 1, 2022 with Mark D. Stolper (incorporated by reference to Exhibit 10.1 filed with Form 8-K on September 2, 2022).
         
    10.11*   Amendment to Employment Agreement dated January 1, 2024 with Mark D. Stolper (incorporated by reference to Exhibit 10.11 filed with Form 10-K on February 29, 2024).
         
    10.12*   Employment Agreement dated September 1, 2022 with Stephen M. Forthuber (incorporated by reference to Exhibit 10.2 filed with Form 8-K on September 2, 2022).
         
    10.13*   Amendment to Employment Agreement dated January 1, 2024 with Stephen M. Forthuber (incorporated by reference to Exhibit 10.13 filed with Form 10-K on February 29, 2024).
         
    10.14*   Employment Agreement dated September 1, 2022 with Norman R. Hames (incorporated by reference to Exhibit 10.3 filed with Form 8-K on September 2, 2022).
         
    10.15*   Amendment to Employment Agreement dated January 1, 2024 with Norman R. Hames (incorporated by reference to Exhibit 10.15 filed with Form 10-K on February 29, 2024).
         
    10.16*   Employment Agreement dated September 1, 2022 with Mital Patel (incorporated by reference to Exhibit 10.4 filed with Form 8-K on September 2, 2022).
         
    10.17*   Amendment to Employment Agreement dated January 1, 2024 with Mital Patel (incorporated by reference to Exhibit 10.17 filed with Form 10-K on February 29, 2024).
         
    10.18*   Employment Agreement dated September 1, 2022 with David J. Katz (incorporated by reference to Exhibit 10.15 filed with Form 10-K on March 1, 2023).

     

     

     

     

     4 

     

     

         
    10.19*   Amendment to Employment Agreement dated January 1, 2024 with David J. Katz (incorporated by reference to Exhibit 10.19 filed with Form 10-K on February 29, 2024).
         
    10.20*   Employment Agreement dated June 1, 2020 with Gregory Sorensen (incorporated by reference to Exhibit 10.1 filed with Form 8-K on August 9, 2023).
         
    10.21*   Employment Agreement, dated September 11, 2024, between Aidence B.V. and Cornelis Wesdorp (incorporated by reference to Exhibit 10.1 filed with Form 8-K on September 12, 2024).
         
    10.22   Amended and Restated Management and Service Agreement between Radnet Management, Inc. and Beverly Radiology Medical Group III dated January 1, 2004 (incorporated by reference to Exhibit 10.16 filed with Form 10-K for the year ended October 31, 2003).
         
    10.23   Second Amended and Restated First Lien Credit and Guaranty Agreement, dated as of April 23, 2021, by and among RadNet Management, Inc., a California corporation, RadNet, Inc., a Delaware corporation, certain subsidiaries and affiliates of RadNet Management, Inc., as Guarantors, the Lenders and other financial institutions from time to time party thereto, and Barclays Bank PLC, as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 filed with Form 8-K on April 26, 2021).
         
    10.24   First Amendment to Second Amended and Restated First Lien Credit and Guaranty Agreement dated March 27, 2023 (incorporated by reference to Exhibit 10.1 filed with Form 8-K on April 4, 2023).
         
    10.25   Third Amended and Restated First Lien Credit and Guaranty Agreement, dated as of April 18, 2024, by and among RadNet Management, Inc., a California corporation, RadNet, Inc., a Delaware corporation, certain subsidiaries and affiliates of RadNet Management, Inc., as Guarantors, the Lenders and other financial institutions from time to time party thereto, and Barclays Bank PLC, as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 filed with Form 8-K on April 18, 2024).
         
    10.26   Amendment No. 1 to Credit and Guaranty Agreement, dated as of November 26, 2024, by and among RadNet Management, Inc., a California corporation, RadNet, Inc., a Delaware corporation, certain subsidiaries and affiliates of RadNet Management, Inc., as Guarantors, the Lenders and other financial institutions from time to time party thereto, and Barclays Bank PLC, as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 filed with Form 8-K on November 26, 2024).
         
    19.1**   Insider Trading Policy.
         
    21.1   List of Subsidiaries (incorporated by reference to Exhibit 21.1 filed with Form 10-K on March 3, 2025).
         
    23.1   Consent of Independent Registered Public Accounting Firm (incorporated by reference to Exhibit 23.1 filed with Form 10-K on March 3, 2025).
         
    24.1   Power of Attorney (incorporated by reference to Signature Page filed with Form 10-K on March 3, 2025).

     

     

     

     

     5 

     

     

         
    31.1 **   CEO Certification pursuant to Section 302.
         
    31.2 **   CFO Certification pursuant to Section 302.
         
    32.1   CEO Certification pursuant to Section 906 (incorporated by reference to Exhibit 32.1 filed with Form 10-K on March 3, 2025).
         
    32.2   CFO Certification pursuant to Section 906 (incorporated by reference to Exhibit 32.1 filed with Form 10-K on March 3, 2025).
         
    97.1*   RadNet, Inc. Policy on Recovery of Erroneously Awarded Compensation adopted November 8, 2023 (incorporated by reference to Exhibit 97.1 filed with Form 10-K on February 29, 2024).
         
    101.INS   XBRL Instance Document
         
    101.LAB   XBRL Label Linkbase Document
         
    101.PRE   XBRL Presentation Linkbase Document
         
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

      

    * Indicates management contract or compensatory plan.

    ** Filed herewith.

     

     

     

     

     

     

     6 
     

     

     

    SIGNATURES

     

    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

      RADNET, INC.
       
    Date: April 28, 2025 /s/ HOWARD G. BERGER, M.D .
        Howard G. Berger, M.D., President,
        Chief Executive Officer and Director

     

     

     

     

     

     

     

     

     

     

     

     7 

     

    Get the next $RDNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    8/12/2021Outperform → Market Perform
    Raymond James
    8/12/2021$39.00Overweight
    Barclays
    More analyst ratings

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹

      First quarter Revenue was negatively impacted by approximately $22 million and Adjusted EBITDA(1) was negatively impacted by approximately $15 million as a result of the Southern California wildfires and severe winter weather conditionsTotal Company Revenue increased 9.2% to $471.4 million in the first quarter of 2025 from $431.7 million in the first quarter of 2024Revenue from the Digital Health reportable segment increased 31.1% to $19.2 million in the first quarter of 2025 from $14.7 million in the first quarter of 2024Aggregate procedural volumes increased 3.6% and same-center procedural volumes decreased 0.3% compared with the first quarter of 2024Total Company Adjusted EBITDA(1) was $4

      5/11/25 4:00:00 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet, Inc. to Present at the Bank of America Securities 2025 Healthcare Conference on May 13th, 2025

      LOS ANGELES, May 09, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Securities 2025 Healthcare Conference in Las Vegas, NV on Tuesday, May 13, 2025 at 5:00 p.m. Pacific Time. There will be simultaneous and archived webcasts available at https://bofa.veracast.com/webcasts/bofa/healthcare2025/id0NMyx8.cfm Details for RadNet's Presentation: Date:Tuesday, May 13, 2025Time:5:00 p.m. Pacific TimeLocat

      5/9/25 6:00:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Across the western healthcare landscape, artificial intelligence (AI) is being increasingly adopted to simplify authorizations and cut through layers of bureaucratic inefficiency. Rather than replacing physicians — a scenario some tech leaders like Bill Gates have speculated about — the goal is to enhance the capabilities of healthcare professionals. Momentum in this space is being driven by recent initiatives from companies like Avant Technologies, Inc. (OTCQB:AVAI), Koninklijke Philips N.V. (NYSE:PHG), HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF), RadNet, Inc. (NASDAQ:RDNT)

      4/29/25 11:10:00 AM ET
      $ICAD
      $PHG
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Electronics
      Medical Specialities

    $RDNT
    SEC Filings

    See more
    • Amendment: SEC Form S-4/A filed by RadNet Inc.

      S-4/A - RadNet, Inc. (0000790526) (Filer)

      5/19/25 5:23:08 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • SEC Form 425 filed by RadNet Inc.

      425 - RadNet, Inc. (0000790526) (Filed by)

      5/13/25 5:15:01 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by RadNet Inc.

      10-Q - RadNet, Inc. (0000790526) (Filer)

      5/12/25 4:09:52 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    See more
    • RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

      Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

      9/12/24 6:00:00 AM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RadNet upgraded by Raymond James with a new price target

      Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

      3/5/25 7:50:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet upgraded by Barclays with a new price target

      Barclays upgraded RadNet from Equal Weight to Overweight and set a new price target of $79.00 from $57.00 previously

      9/6/24 7:50:42 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • Barclays initiated coverage on RadNet with a new price target

      Barclays initiated coverage of RadNet with a rating of Equal Weight and set a new price target of $48.00

      3/6/24 8:01:30 AM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Financials

    Live finance-specific insights

    See more
    • RadNet Reports First Quarter Financial Results and Revises Upwards 2025 Financial Guidance Ranges for Revenue and Adjusted EBITDA¹

      First quarter Revenue was negatively impacted by approximately $22 million and Adjusted EBITDA(1) was negatively impacted by approximately $15 million as a result of the Southern California wildfires and severe winter weather conditionsTotal Company Revenue increased 9.2% to $471.4 million in the first quarter of 2025 from $431.7 million in the first quarter of 2024Revenue from the Digital Health reportable segment increased 31.1% to $19.2 million in the first quarter of 2025 from $14.7 million in the first quarter of 2024Aggregate procedural volumes increased 3.6% and same-center procedural volumes decreased 0.3% compared with the first quarter of 2024Total Company Adjusted EBITDA(1) was $4

      5/11/25 4:00:00 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call

      LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2025 financial results on Monday, May 12, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1717619&tp_key=f0980d090d. An archived r

      4/24/25 6:00:00 AM ET
      $RDNT
      Medical Specialities
      Health Care
    • RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

      The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancerThe transaction is expected to add to RadNet's wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countriesWith iCAD's seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet's growth and leadership in cancer screening and artificial intelligenceFollowing the completion of the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio of solutionsRadNet will host a conference call and

      4/15/25 4:01:37 PM ET
      $ICAD
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Specialities

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/12/24 4:51:53 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      11/4/24 1:22:38 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RadNet Inc.

      SC 13G/A - RadNet, Inc. (0000790526) (Subject)

      10/24/24 6:36:21 PM ET
      $RDNT
      Medical Specialities
      Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres & COO-Eastern Operations Forthuber Stephen M converted options into 2,760 shares and sold $1,135,599 worth of shares (18,820 units at $60.34), decreasing direct ownership by 3% to 535,182 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      5/20/25 4:15:10 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Director Levitt Lawrence L sold $305,450 worth of shares (5,000 units at $61.09), decreasing direct ownership by 3% to 164,957 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      5/20/25 4:15:08 PM ET
      $RDNT
      Medical Specialities
      Health Care
    • Pres and COO-West Operations Hames Norman R converted options into 2,760 shares and sold $506,820 worth of shares (8,447 units at $60.00), decreasing direct ownership by 1% to 249,183 units (SEC Form 4)

      4 - RadNet, Inc. (0000790526) (Issuer)

      5/15/25 8:43:59 PM ET
      $RDNT
      Medical Specialities
      Health Care